Levels of soluble XXXX in serum associated with severity of @entity779 due to @entity5 necrosis factor alpha stimulation.

@entity1 @entity8034 @entity697 @entity5 @entity310 @entity687 @entity8389 @entity7643 @entity779 @entity688
The @entity8034 ( @entity8034 ), also known as @entity8389 , has been shown previously to regulate T-cell function and is produced by T cells and endothelial cells. It was reported recently to be elevated in mild @entity779 @entity1 during @entity697 . The @entity8389 gene encodes several splice products: L (long), V (short) and s (soluble). A cohort of 38 @entity1 with @entity7643 ( @entity7643 ) and mild @entity779 ( @entity779 ) were evaluated using a secreted soluble @entity8389 (sST2) ELISA. The RNA expression of @entity8389 was evaluated by real-time quantitative RT-PCR using @entity1 ' peripheral blood mononuclear cells (PBMCs) and in vitro using @entity1 umbilical vein endothelial cells (HUVECs) exposed to sera from @entity779 @entity1 . @entity7643 @entity1 had higher levels of serum sST2, @entity5 necrosis factor alpha ( @entity310 ), @entity687 and @entity688 compared with @entity779 @entity1 and normal healthy control individuals. However, viraemia was indistinguishable between mild and severe cases. No changes in @entity8389 mRNA expression were found in PBMCs from these two groups of @entity779 @entity1 . In vitro, sST2 was elevated in HUVECs treated with @entity1 sera. Neutralization of @entity310 in @entity1 sera by pre-treatment with a @entity310 antibody inhibited the upregulation of sST2 expression in HUVECs. These results implicate serum @entity310 in the modulation of expression of sST2 in an in vitro system, and indicate that sST2 could be associated with the severity of disease. Further studies to determine whether sST2 levels are predictive of the severe form of the disease and the role of sST2 in immune regulation are warranted.
